898. Effectiveness and Tolerability of DTG + 3TC in Clinical Practice: Evidence in PLHIV from Real-world Data

BACKGROUND: Randomized controlled trials have shown dolutegravir (DTG) + lamivudine (3TC) to be an efficacious, well-tolerated and durable regimen for treatment-naive and treatment-experienced people living with HIV (PLHIV). Several observational studies have also concluded that it is effective in c...

Descripción completa

Detalles Bibliográficos
Autores principales: Evitt, Lee A, Kumar, Rahul, Kamath, Rahul, Jha, Diwakar, Parks, Daniel, van Wyk, Jean A, de Ruiter, Annemiek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644882/
http://dx.doi.org/10.1093/ofid/ofab466.1093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644882/
http://dx.doi.org/10.1093/ofid/ofab466.1093

Ejemplares similares